The Cancer Letter

Inside information on cancer research and drug development

Vol.
31
No.
35
September 30, 2005Sep 30, 2005
Free
DOWNLOAD THE PDF

White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns.

Von Eschenbach says he will continue as NCI director and give both jobs “100 percent.”

Members of Congress say that won’t work.

Legal experts say too many conflicts involved. HHS gave von Eschenbach a waiver for his role in C-Change.

After a “humble” start at NCI, von Eschenbach set unachievable goal.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account